A Phase 2/3 interventional study of Basimglurant and Placebo in Trigeminal Neuralgia, sponsored by Noema Pharma AG. Active, not recruiting at 34 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Noema Pharma AG · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2/3, reaches primary completion later than 4 of the 10 other live ones, and was the 27th registered.
140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.
Browse Trigeminal Neuralgia studies →7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 40 across 93 interventional studies indexed under Trigeminal Neuralgia.
Median enrollment 29 across the 26 interventional studies, 56 across the 8 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
Noema Pharma AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
Noema Pharma AG has 2 studies filed under Trigeminal Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Trigeminal Neuralgia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05217628Phase 3Noema Pharma AGAn Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | 2027-02-02 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT06216886Stanford UniversityOnabotulinumtoxinA for Trigeminal Neuralgia | 2027-02-01 |
| NCT05269472University of MinnesotaTrigeminal Neuralgia Electrophysiology | 2027-11-01 |
| NCT05738096University of MinnesotaTrigeminal Evoked Responses to Improve Rhizotomy | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.
This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.
This study is designed to evaluate the efficacy and safety of basimglurant (NOE-101) in patients with TN. Basimglurant is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5) which controls a wide range of processes in both central and peripheral nervous system. Inhibition of the mGluR5 receptor has shown therapeutic potential for pain associated with conditions such as TN. The drug has been shown to have a favorable safety profile in adults, children and adolescents. The aim of the study is to determine whether Basimglurant decreases both duration and intensity of facial pain associated with TN by use of a patient pain diary and the Patient-reported Global Impression of Change (PGI-C) compared to baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Summary):
Patients who meet any of the following criteria will be excluded from participation in this study:
Patients with secondary TN as per the ICHD-3 criteria.
Medication history:
Any investigational drug within 90 days prior to initiation of study drug.
Medical status:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Period 1 (Run-in: Baseline1 to Week 8): Basimglurant once daily dosing starting dose 1.5mg * Period 2 (Double blind: Weeks 9 to 20): Participants will receive double-blind treatment with Basimglurant once daily. * Open-label Extension (OLE): On completion of Period 2, participants will be offered open label treatment with Basimglurant in an open label extension for up to 52 weeks.
Drug: Basimglurant
\- Period 2 (Double blind: Week 9 to Week 20): Participant randomized to placebo will receive the corresponding number of matching placebo capsules.
Other: Placebo
Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability. Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo. OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1.
Also known as: NOE-101
Participant randomized to receive matching placebo once daily.
Period 1: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.
Change in pain as measured by the pain diary (TnED).
Time frame: 8 weeks
Period 2: Time to Loss of Efficacy or pain recurrence defined as the confirmed increase in the number of weekly paroxysms or re-emergence of continuous pain and/or the need for rescue medication.
To assess the maintenance of effect on pain.
Time frame: 12 weeks
Open Label Extension: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.
To evaluate the long-term safety of basimglurant daily dosing.
Time frame: 52 weeks
Period 2: Mean change in the total patient-rated Penn-Facial Pain Scale-Revised (Penn-FPS-R) scale compared with Period 2 baseline (BL2).
Impact on facial pain.
Time frame: 12 weeks
Period 2: Frequency of attacks (paroxysms).
Impact on facial pain measured by patient rated scale via Penn-FPS-R
Time frame: 12 weeks
Period 2: Severity of attacks (paroxysms).
Impact on facial pain measured by patient rated scale via Penn-FPS-R
Time frame: 12 weeks
Period 2: Severity of continuous pain.
Impact on facial pain measured by patient rated scale via Penn-FPS-R
Time frame: 12 weeks
Period 2: Duration of continuous pain.
Impact on facial pain measured by patient rated scale via Penn-FPS-R
Time frame: 12 weeks
Period 2: Change in Patient Global Impression of Change (P-GIC).
Impact on facial pain.
Time frame: 12 weeks
Period 2: Change in Medication Satisfaction Questionnaire (MSQ).
Impact on facial pain.
Time frame: 12 weeks
Open Label Extension: Frequency of attacks (paroxysms).
Evaluate the continued efficacy of basimglurant on facial pain measured by patient rated scale via Penn-FPS-R
Time frame: 52 weeks
Open Label Extension: Severity of attacks (paroxysms).
Evaluate the continued efficacy of basimglurant on facial pain measured by patient rated scale via Penn-FPS-R
Time frame: 52 weeks
Open Label Extension: Severity and duration of continuous pain reported in patient pain diary.
Evaluate the continued efficacy of basimglurant on facial pain.
Time frame: 52 weeks
Open Label Extension: Measure Global Impression of Severity as captured by PGI-S.
Evaluate the continued efficacy of basimglurant on facial pain.
Time frame: 52 weeks
Period 1: Mean change from Period 1 baseline (BL1) to Week 8 in the total patient-rated Penn-Facial Pain Scale-Revised (Penn-FPS-R) scale.
Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 1: Measure Global Impression of change from Period 1 baseline (BL1) to Week 8.
Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 1: Number and severity of attacks (paroxysms).
Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 1: Duration of continuous pain compared with BL1.
Evaluate 8-week once daily basimglurant on pain associated with TN on the following as measured by patient rated scale via Penn-FPS-R: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 1: Severity of continuous pain compared with BL1.
Evaluate 8-week once daily basimglurant on pain associated with TN on the following as measured by patient rated scale via Penn-FPS-R: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 1: Number of pain free days.
Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 1: Patient reported rating of the Medication Satisfaction Questionnaire (MSQ).
Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction
Time frame: 8 weeks
Period 2: The impact of pain on general activities of daily living captured in patient diary cards.
Time frame: 12 weeks
Started Jan 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Basimglurant
Noema Pharma AG